The effect of malignancy on prognosis in ICU patients with COVID-19

Abstract

Background: It is known that COVID-19 has a worse and poorer progression, which often might lead to death in those with comorbidities. Multiple studies have recently examined the clinical course of cancer patients with COVID-19 and new guidelines have been developed to manage this group of patients. This study aimed to evaluate the clinical course and mortality rate of cancer patients admitted to the intensive care unit (ICU) for COVID-19. Material and Method: The demographic characteristics, detailed medical history and laboratory findings of 140 patients with malignancy, who were treated in the COVID-19 Intensive Care Unit of Ankara City Hospital, were evaluated retrospectively. Gender, age, comorbidity, length of stay in the ICU, mortality rates, length of stay on a mechanical ventilator, cytokine storm scores, ferritin, interleukin 6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT), D-dimer, lactate dehydrogenase (LDH), lymphocyte count and treatment options were compared. The patients were divided into two groups: solid and hematological malignancies. Results: One hundred eight of 140 patients were diagnosed with solid organ malignancy and 32 with hematological malignancy. The most common comorbidity was found to be hypertension. A total of 94 patients died during their ICU stay. While the most common solid organ malignancies were malignancies of the lower gastrointestinal tract and lung cancers, multiple myeloma (MM) was the most common hematological malignancy. There was no significant difference between the two groups in terms of cytokine storm scores , duration of hospitalization and mechanical ventilation. Levels of Ferritin and LDH were found to be significantly higher in patients with hematological malignancies, while D-dimer was significantly higher in solid organ malignancies. A high level of CRP and IL-6 was associated with COVID-19 mortality. Lymphopenia was associated with increased mortality in patients with solid organ malignancy. However, there was no difference in mortality rate among both groups. Although the mortality was significantly higher in the patient group receiving chemotherapy, there were no significant differences in mortality for the duration of receiving chemotherapy. Conclusion: The results of this study suggested that cancer was associated with severe clinical outcomes and a 67% mortality rate among patients with COVID-19. However, despite the changes in patients’ demographic, clinical and laboratory characteristics, no difference in mortality rate was detected in patients with hematological and solid organ malignancies due to COVID-19 infection.

Keywords

• COVID-19
• coronaviruses
• hematological malignancies
• malignancy
• solid malignancies
• mortality

References

1. Gürsoy C, Oral Tapan Ö, Doğan E, Pektaş S, Demirbilek S. Early and late results of intravenous immunoglobulin as potential adjuvant therapies in critically ill COVID-19 patients: a retrospective cohort study. J Health Sci Med 2022; 5: 794-8.
2. Gemcioğlu E, Başer S, İnan O, et al. Effects of blood group types on risk of infection, disease severity and mortality in COVID-19 patients. J Health Sci Med 2022; 5: 374-8.
3. Ayyıldız A, Çobaner N, Erben N, Yelken B. A retrospective, observational study: early versus late favipiravir in COVID-19 pneumonia. J Med Palliat Care 2022; 3: 22-5.
4. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China JAMA Neurol 2020; 77: 683-90.
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
6. Zengin M, Karcioglu AM. Do not invade, just support. Bratisl Lek Listy 2022; 123: 218-26.
7. Zengin M, Baldemir R. Investigation of the global outcomes of acute respiratory distress syndrome with the effect of COVID-19 in publications: a bibliometric analysis BETWEEN 1980 and 2020. KırıkkaleÜniversitesi Tıp Fakültesi Derg 2021; 23: 279-92.
8. Ejaz H, Alsrhani A, Zafar A et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health 2020; 13: 1833-9.

9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
10. Liang W, Guan W, Chen R, Wang W, Li J, Xu K. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21: 335–7.
11. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov 2020; 10: 935-41
12. Zeidan AM, Boddu PC, Patnaik MM, et al. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of in-ternational experts. Lancet Haematology 2020; 7: e601-12.
13. Wang Q, Berger NA, Xu R. Analyses of Risk, racial disparity and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncology 2021; 7: 220–7.
14. Zhang H-Y, Wang L-W, Chen Y-Y, et al. A multicentre study of 2019 novel coronavirus dise-ase outcomes of cancer patients in Wuhan, China. medRxiv (2020) (Epub ahead of print).
15. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol2020; 31: 894-901.
16. https://www.ashresearchcollaborative.org/s/covid-19-registry/data-summaries(Last access: May 25, 2021)
17. García-Suárez J, De la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based re-gistry study. J Hematol Oncol 2020; 13: 133.
18. Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies. J Hematol Oncol 2021 14; 14: 168.